Biocon Biologics Acquires Viatris’ Biosimilar Portfolio for US$3.3 B
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 3 (Table of Contents)
Published: 2 Mar-2022
DOI: 10.3833/pdr.v2022.i3.2676 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Biocon Biologics, a subsidiary of Biocon, has agreed to acquire Viatris’ biosimilar business in a cash-and-stock deal worth up to US$3...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS